newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - XERIS BIOPHARMA HOLDINGS INC

  • Explicit Guidance:

    • Raised 2024 revenue guidance to $395–$405 million, representing ~37% growth at the midpoint.
    • Raised 2030 total revenue outlook to >$1 billion (up from $750 million), driven by Recorlev, GVoke, and Cavexas.
    • Recorlev trajectory updated to reach $1 billion in peak sales by 2030–2032 (previously projected for 2035).
    • Recorlev Q3 sales of $71 million established a new growth trajectory; implied full-year 2027 revenue of ~$350 million (analyst calculation based on management confirmation of "better" than this figure).
    • 8121 (hypothyroidism) targeted for top-line Phase 3 data by end of 2028 and approval in 2030, with peak sales potential of $1–$3 billion.
    • Company remains profitable with gross margins of 88% and improving quarterly.
  • Business-Segment Outlook:

    • Recorlev (Cushing's disease): Identified as the primary growth engine; sales force doubled in January to capitalize on increased screening for resistant diabetes, hypertension, and obesity. Guidelines (ADA, ESAD) now recommend cortisol testing for resistant cases, expanding the prescriber base from endocrinologists to primary care physicians. Over 60% of new patients are therapy-naïve.
    • GVoke (Hypoglycemia): Returning to growth mode with expected high single-digit to low double-digit growth indefinitely; targets the ~15 million diabetic population recommended for glucagon access but currently underserved (<1 million users).
    • Cavexas (Primary Periodic Paralysis): Transitioned from flat/steady to a growth curve following incremental Q4 investments in field personnel to identify 4,000–5,000 potential patients.
    • 8121 (Levothyroxine): Once-weekly subcutaneous product targeting 3–5 million patients failing oral therapy; expected to drive material revenue contribution starting in 2030.
    • Sales Force & Penetration: Recorlev sales expansion accelerated faster than anticipated (3–6 months vs. typical 6–9 months); GVoke and Cavexas require continued practice pattern changes and patient support to drive adoption.
  • Market and Competitive Outlook:

    • Demand Trends: Hypercortisolism screening is accelerating due to guideline changes regarding resistant metabolic disease; similar practice change efforts required for glucagon (GVoke) and levothyroxine (8121) adoption.
    • Payer Access: Current payer dynamics involve strict prior authorization and medical necessity criteria for rare disease categories; management does not anticipate immediate payer restrictions on Recorlev due to the small, specific patient population.
    • Competitive Landscape: 8121 addresses a market with 40+ years of minimal innovation; KOL enthusiasm for the once-weekly format is high, with independent scientific sessions highlighting the asset.
  • Macro / Industry Outlook:

    • Regulatory Environment: FDA alignment secured for 8121's non-inferiority trial design; guidelines from ADA/ESAD and medical necessity criteria are driving prescriber adoption.
    • Market Dynamics: Payer willingness to approve 8121 is predicated on focusing on the highest unmet need (20–25% of treated patients failing oral therapy); success relies on demonstrating failure on existing oral levothyroxine.
  • Strategic Initiatives:

    • Phase 3 Launch: 8121 Phase 3 "Cornerstone" non-inferiority trial (500 participants) to be initiated by end of 2024; comparative study vs. oral levothyroxine.
    • Ancillary Studies: "Touchstone" special population study (poorly controlled patients) to launch in 2025; "Capstone" pediatric study; and real-world evidence (RWE) generation to support access.
    • M&A / Business Development (BD): Prioritizing disciplined BD to leverage commercial engine in ultra-rare, rare, and endocrinology; targeting assets contributing revenue/growth within 3–6 years prior to 8121's full P&L impact.
    • Capacity/Investment: Increased Q4 investment in field personnel for Cavexas and continued expansion of Recorlev commercial footprint.
  • Risks and Headwinds to Outlook:

    • Patient Persistence: Risk of patient drop-out in first 3–4 months of Recorlev therapy due to cortisol withdrawal and complex medication adjustments for comorbidities.
    • Adoption Speed: GVoke and 8121 adoption dependent on shifting entrenched physician practices and ensuring patient compliance with new protocols.
    • Payer Restrictions: Potential for future payer restrictions on Recorlev, though management views current low patient volume as a mitigator.
    • Execution Risk: 8121 success dependent on achieving non-inferiority in Phase 3 and securing sufficient access via RWE and special population data.
  • Management Tone on the Future:

    • Confidence: High confidence in 2030 revenue targets and 8121 approval probability ("very high probability path to approval").
    • Acceleration: Management emphasizes an acceleration of growth trends, specifically noting Recorlev's performance is "better than even we expected" and "on a new growth trend."
    • Discipline: While aggressive on growth, BD approach remains "disciplined" to ensure execution capabilities match acquisition targets.
    • Guidance Changes: Significant upward revision of 2024 and 2030 guidance reflects confidence in the triple-product growth engine and the 8121 pipeline.
  • Miscellaneous:

    • 8121 pricing guidance deferred until 2030 approval, but assumptions considered "conservative and achievable."
    • Target to achieve peak 8121 sales with only 10% capture of the 3–5 million addressable patient population.
    • Company status: Profitable for over a year, utilizing excess cash for growth investments and BD.
Company
XERIS BIOPHARMA HOLDINGS INC
Keywords
XERIS BIOPHARMA HOLDINGS INC